Dermatology Biologics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global dermatology biologics market is poised for substantial growth, expected to reach a value of US$ 5.7732 billion in 2024 and projected to increase to US$ 9.64665 billion by 2031, with a robust Compound Annual Growth Rate (CAGR) of 7.6%%. This expansion reflects the escalating demand for dermatology biologics worldwide. Dermatology biologics market is witnessing robust growth, fueled by various factors contributing to its expansion and adoption worldwide. From technological advancements to regulatory approvals, market dynamics are shaping the landscape of dermatology biologics, offering both opportunities and challenges for industry stakeholders.

Demand Dynamics: Demand for dermatology biologics is further augmented by their approval for pediatric psoriasis treatment, addressing a previously unmet medical need in children with moderate to severe psoriasis. However, challenges persist, including the escalating cost of biologic therapies and limited awareness about skin diseases and biologic treatments, particularly in low-middle-income countries. The lack of education and awareness impedes market growth in these regions, presenting a barrier to adoption and market expansion.

Regional Insights: In the U.S., the dermatology biologics market is thriving, driven by increasing FDA approvals for biologic treatments and pharmaceutical companies' efforts to promote biological treatments for prevalent conditions like acne, eczema, and psoriasis. The U.K. presents opportunities for dermatology biologics manufacturers, with the biopharmaceutical industry driving demand and significant advancements made by multinational corporations and smaller biotech firms.

China is emerging as a prominent market for dermatology biologics, boasting the largest market share in East Asia. Rising patient preference for biological treatments, driven by their efficacy and targeted therapy, fuels market growth in the country.

Product and End-User Analysis: Tumor necrosis factor (TNF) inhibitors dominate the dermatology biologics market, particularly for treating psoriasis in adults. This segment holds approximately 54.4% of the overall market share, driven by the increasing prevalence of psoriasis worldwide.

Hospital pharmacies serve as a key distribution channel for dermatology biologics, accounting for a significant market share. The growing number of skin cancer patients seeking treatment in hospitals contributes to the demand for biologics, with patients preferring the reliability and convenience of hospital pharmacies.

Competitive Analysis:

Leading manufacturers in the dermatology biologics market are focused on obtaining regulatory approvals and expanding their product lines. Strategies such as mergers, acquisitions, and partnerships are prevalent, aimed at strengthening product offerings and market accessibility. Key players in the market include Merck and Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., AstraZeneca, Celgene Corporation, Eli Lilly and Company, and Johnson and Johnson (Janssen Biotech Inc.).

Examples of recent strategic initiatives include AbbVie securing European Medicines Agency approval for upadacitinib (RINVOQ(R)), Amgen and Generate Biomedicines collaborating to develop protein therapeutics across various therapeutic areas, and Samsung Biologics and AstraZeneca expanding their manufacturing partnerships to enhance COVID and cancer therapy facilities.

Key Market Segments Covered in Dermatology Biologics Industry Research

Dermatology Biologics Market by Product Type:

Interleukin Inhibitors
Tumor Necrosis Factor Inhibitors

Dermatology Biologics Market by End User:

Hospital Pharmacies
Retail Pharmacies
e-Commerce

Dermatology Biologics Market by Region:

North America Dermatology Biologics Market
Latin America Dermatology Biologics Market
Europe Dermatology Biologics Market
South Asia Dermatology Biologics Market
East Asia Dermatology Biologics Market
Oceania Dermatology Biologics Market
The Middle East & Africa Dermatology Biologics Market

1. Executive Summary

1.1. Global Dermatology Biologics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Dermatology Biologics Market Outlook, 2018 - 2031

3.1. Global Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Interleukin Inhibitors
  - 3.1.1.2. Tumor Necrosis Factor Inhibitors
3.2. Global Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospital Pharmacies
  - 3.2.1.2. Retail Pharmacies
  - 3.2.1.3. e-Commerce
3.3. Global Dermatology Biologics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Dermatology Biologics Market Outlook, 2018 - 2031

4.1. North America Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Interleukin Inhibitors
  - 4.1.1.2. Tumor Necrosis Factor Inhibitors
4.2. North America Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacies
  - 4.2.1.2. Retail Pharmacies
  - 4.2.1.3. e-Commerce
- 4.2.2. Market Attractiveness Analysis
4.3. North America Dermatology Biologics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
- 4.3.2. Market Attractiveness Analysis

5. Europe Dermatology Biologics Market Outlook, 2018 - 2031

5.1. Europe Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Interleukin Inhibitors
  - 5.1.1.2. Tumor Necrosis Factor Inhibitors
5.2. Europe Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacies
  - 5.2.1.2. Retail Pharmacies
  - 5.2.1.3. e-Commerce
- 5.2.2. Market Attractiveness Analysis
5.3. Europe Dermatology Biologics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
- 5.3.2. Market Attractiveness Analysis

6. Asia Pacific Dermatology Biologics Market Outlook, 2018 - 2031

6.1. Asia Pacific Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Interleukin Inhibitors
  - 6.1.1.2. Tumor Necrosis Factor Inhibitors
6.2. Asia Pacific Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacies
  - 6.2.1.2. Retail Pharmacies
  - 6.2.1.3. e-Commerce
- 6.2.2. Market Attractiveness Analysis
6.3. Asia Pacific Dermatology Biologics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
- 6.3.2. Market Attractiveness Analysis

7. Latin America Dermatology Biologics Market Outlook, 2018 - 2031

7.1. Latin America Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Interleukin Inhibitors
  - 7.1.1.2. Tumor Necrosis Factor Inhibitors
7.2. Latin America Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospital Pharmacies
  - 7.2.1.2. Retail Pharmacies
  - 7.2.1.3. e-Commerce
- 7.2.2. Market Attractiveness Analysis
7.3. Latin America Dermatology Biologics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
- 7.3.2. Market Attractiveness Analysis

8. Middle East & Africa Dermatology Biologics Market Outlook, 2018 - 2031

8.1. Middle East & Africa Dermatology Biologics Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Interleukin Inhibitors
  - 8.1.1.2. Tumor Necrosis Factor Inhibitors
8.2. Middle East & Africa Dermatology Biologics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacies
  - 8.2.1.2. Retail Pharmacies
  - 8.2.1.3. e-Commerce
8.3. Middle East & Africa Dermatology Biologics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Dermatology Biologics Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Dermatology Biologics Market by End User, Value (US$ Bn), 2018 - 2031
- 8.3.2. Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Merck and Co. Inc.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Novartis AG
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Pfizer Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. AbbVie Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Amgen Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. AstraZenca
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Celgene Corporation
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Eli Lilly and Company
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Johnson and Johnson (Janssen Biotech Inc.)
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations